RegenETP Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de RegenETP.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme RegenETP n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OTCPK:RGTP.Q - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
3/31/2023	0	-8	-22	-22	N/A
12/31/2022	1	-8	-23	-23	N/A
9/30/2022	2	-16	-26	-26	N/A
6/30/2022	3	-13	-26	-26	N/A
3/31/2022	5	-17	-22	-22	N/A
12/31/2021	9	-30	-23	-23	N/A
9/30/2021	12	-32	-21	-21	N/A
6/30/2021	14	-38	-23	-23	N/A
3/31/2021	14	-47	-31	-31	N/A
12/31/2020	10	-43	-39	-38	N/A
9/30/2020	8	-54	-50	-48	N/A
6/30/2020	6	-70	-55	-53	N/A
3/31/2020	5	-80	-57	-55	N/A
12/31/2019	6	-92	-59	-57	N/A
9/30/2019	7	-128	-70	-69	N/A
6/30/2019	7	-125	-69	-66	N/A
3/31/2019	6	-116	-64	-60	N/A
12/31/2018	4	-111	-53	-48	N/A
10/31/2018	2	-74	-38	-29	N/A
7/31/2018	0	-62	-27	-20	N/A
4/30/2018	0	-50	-20	-15	N/A
1/31/2018	0	-141	-16	-12	N/A
10/31/2017	N/A	-131	-10	-8	N/A
7/31/2017	N/A	-121	-7	-5	N/A
4/30/2017	-1	-118	-5	-3	N/A
1/31/2017	-1	-8	N/A	-2	N/A
10/31/2016	N/A	-10	N/A	-2	N/A
7/31/2016	0	-10	N/A	-2	N/A
4/30/2016	3	-9	N/A	-4	N/A
1/31/2016	4	-11	N/A	-4	N/A
10/31/2015	7	-6	N/A	-2	N/A
7/31/2015	13	-11	N/A	-4	N/A
4/30/2015	14	-13	N/A	-2	N/A
1/31/2015	16	-13	N/A	-2	N/A
10/31/2014	34	-16	N/A	-4	N/A
7/31/2014	38	-15	N/A	-6	N/A
4/30/2014	39	-16	N/A	-13	N/A
1/31/2014	46	-15	N/A	-12	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de RGTP.Q est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de RGTP.Q devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de RGTP.Q devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de RGTP.Q devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de RGTP.Q devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de RGTP.Q devrait être élevé dans 3 ans

RegenETP Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Consensus forecasts updated

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

PolarityTE to raise up to $10M with at-the-market offering

New 90-day high: US$1.32

PolarityTE under pressure on pricing $8M registered direct offering

New 90-day low: US$0.63

PolarityTE perks up after securing first U.S. patent

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.18 loss per share